Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03407144
Title Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Merck Sharp & Dohme Corp.
Indications

Hodgkin's lymphoma

Therapies

Cyclophosphamide + Doxorubicin + Etoposide + Pembrolizumab + Prednisone + Vincristine Sulfate

Bleomycin + Dacarbazine + Doxorubicin + Pembrolizumab + Vinblastine

Age Groups: adult | child
Covered Countries USA | ITA | FRA | ESP | DEU


No variant requirements are available.